Maintenance Therapy
Gefitinib NSCLC maintenance therapy
Abstract
Dr. Zhang and co-authors have demonstrated that
gefitinib “maintenance therapy” of newly diagnosed east
Asian non-small cell lung cancer (NSCLC) patients who
were progression-free after four cycles of platinum-based
doublet chemotherapy, resulted in a significant increase in
progression free survival (PFS) and objective response rate
without a concomitant increase in overall survival (OS).
gefitinib “maintenance therapy” of newly diagnosed east
Asian non-small cell lung cancer (NSCLC) patients who
were progression-free after four cycles of platinum-based
doublet chemotherapy, resulted in a significant increase in
progression free survival (PFS) and objective response rate
without a concomitant increase in overall survival (OS).
